{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:03:02Z","timestamp":1771272182886,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03440-z","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T08:29:39Z","timestamp":1764750579000},"page":"451-467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Lebrikizumab on Pruritus: A Narrative Review"],"prefix":"10.1007","volume":"43","author":[{"given":"Gil","family":"Yosipovitch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina B.","family":"Elmariah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangeline","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"12","key":"3440_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S Stander","year":"2021","unstructured":"Stander S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136\u201343.","journal-title":"N Engl J Med"},{"issue":"5","key":"3440_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.clindermatol.2018.05.007","volume":"36","author":"R Sacotte","year":"2018","unstructured":"Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595\u2013605. https:\/\/doi.org\/10.1016\/j.clindermatol.2018.05.007.","journal-title":"Clin Dermatol"},{"issue":"2","key":"3440_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/bjd.14167","volume":"174","author":"TL Diepgen","year":"2016","unstructured":"Diepgen TL, Ofenloch RF, Bruze M, Bertuccio P, Cazzaniga S, Coenraads PJ, et al. Prevalence of contact allergy in the general population in different European regions. Br J Dermatol. 2016;174(2):319\u201329.","journal-title":"Br J Dermatol"},{"issue":"3","key":"3440_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","volume":"74","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2015.10.043.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3440_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"3440_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1067\/mai.2003.174","volume":"111","author":"BG Bender","year":"2003","unstructured":"Bender BG, Leung SB, Leung DY. Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure. J Allergy Clin Immunol. 2003;111(3):598\u2013602. https:\/\/doi.org\/10.1067\/mai.2003.174.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3440_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/jid.2014.325","volume":"135","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Investig Dermatol. 2015;135(1):56\u201366. https:\/\/doi.org\/10.1038\/jid.2014.325.","journal-title":"J Investig Dermatol"},{"key":"3440_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-031-54513-9_3","volume":"1447","author":"WD Boothe","year":"2024","unstructured":"Boothe WD, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2024;1447:21\u201335.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"3440_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54\u201362.","journal-title":"Allergy"},{"issue":"5","key":"3440_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657\u201382. https:\/\/doi.org\/10.1111\/jdv.14891.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"3440_CR11","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.jid.2021.02.714","volume":"141","author":"G Isola","year":"2021","unstructured":"Isola G, Gimenez-Riviera V, Jack C. 684 distinct IL-13 production and accumulation in lesional and non-lesional skin of atopic dermatitis patients. J Investig Dermatol. 2021;141(5):S119.","journal-title":"J Investig Dermatol"},{"key":"3440_CR12","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-071812","author":"JJ Schoch","year":"2025","unstructured":"Schoch JJ, Anderson KR, Jones AE, Tollefson MM, Section on Dermatology. Atopic dermatitis: update on skin-directed management: clinical report. Pediatrics. 2025. https:\/\/doi.org\/10.1542\/peds.2025-071812.","journal-title":"Pediatrics"},{"issue":"4","key":"3440_CR13","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","volume":"127","author":"M Suarez-Farinas","year":"2011","unstructured":"Suarez-Farinas M, Tintle SJ, Shemer A, Chiricozzi A, Nograles K, Cardinale I, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127(4):954-964 e1-4.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3440_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40257-024-00913-9","volume":"26","author":"J Gorelick","year":"2025","unstructured":"Gorelick J, Nguyen A, Schneider SKR, Martel BC, Madsen DE, Armstrong AW. Biomarkers in atopic dermatitis: a review of the role of IL-13 and the impact of tralokinumab treatment. Am J Clin Dermatol. 2025;26(2):199\u2013211.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"3440_CR15","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","volume":"9","author":"T Ratchataswan","year":"2021","unstructured":"Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for treatment of atopic dermatitis: current status and future prospect. J Allergy Clin Immunol Pract. 2021;9(3):1053\u201365. https:\/\/doi.org\/10.1016\/j.jaip.2020.11.034.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"3440_CR16","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.009.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"3440_CR17","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1111\/1346-8138.16116","volume":"48","author":"PH Chang","year":"2021","unstructured":"Chang PH, Huang SF, Chang PS, Yu Y. Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications. J Dermatol. 2021;48(11):1631\u20139. https:\/\/doi.org\/10.1111\/1346-8138.16116.","journal-title":"J Dermatol"},{"issue":"1","key":"3440_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S2468-1253(22)00397-1","volume":"8","author":"The Lancet Gastroenterology and Hepatology","year":"2023","unstructured":"The Lancet Gastroenterology and Hepatology. New restrictions on JAK inhibitors in the EU. Lancet Gastroenterol Hepatol. 2023;8(1):1.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3440_CR19","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-1-7","author":"F Goncalves","year":"2021","unstructured":"Goncalves F, Freitas E, Torres T. Selective IL-13 inhibitors for the treatment of atopic dermatitis. Drugs Context. 2021. https:\/\/doi.org\/10.7573\/dic.2021-1-7.","journal-title":"Drugs Context"},{"issue":"1","key":"3440_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14712598.2024.2435427","volume":"25","author":"L Stingeni","year":"2025","unstructured":"Stingeni L, Ferrucci S, Amerio P, Foti C, Patruno C, Girolomoni G. Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis. Expert Opin Biol Ther. 2025;25(1):15\u201320. https:\/\/doi.org\/10.1080\/14712598.2024.2435427.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"3440_CR21","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.it.2018.10.001","volume":"39","author":"MR Mack","year":"2018","unstructured":"Mack MR, Kim BS. The itch-scratch cycle: a neuroimmune perspective. Trends Immunol. 2018;39(12):980\u201391. https:\/\/doi.org\/10.1016\/j.it.2018.10.001.","journal-title":"Trends Immunol"},{"issue":"6","key":"3440_CR22","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.conb.2011.10.012","volume":"21","author":"SE Ross","year":"2011","unstructured":"Ross SE. Pain and itch: insights into the neural circuits of aversive somatosensation in health and disease. Curr Opin Neurobiol. 2011;21(6):880\u20137. https:\/\/doi.org\/10.1016\/j.conb.2011.10.012.","journal-title":"Curr Opin Neurobiol"},{"key":"3440_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.644760","volume":"8","author":"FJ Legat","year":"2021","unstructured":"Legat FJ. Itch in atopic dermatitis\u2014what is new? Front Med (Lausanne). 2021;8:644760. https:\/\/doi.org\/10.3389\/fmed.2021.644760.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"3440_CR24","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljad022.","journal-title":"Br J Dermatol"},{"issue":"12","key":"3440_CR25","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Thaci D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391.","journal-title":"N Engl J Med"},{"issue":"2","key":"3440_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","volume":"159","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159(2):182\u201391.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"3440_CR27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40257-023-00793-5","volume":"24","author":"D Bernardo","year":"2023","unstructured":"Bernardo D, Bieber T, Torres T. Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2023;24(5):753\u201364.","journal-title":"Am J Clin Dermatol"},{"key":"3440_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.099","author":"A Alexis","year":"2024","unstructured":"Alexis A, Moiin A, Waibel J, Wallace P, Cohen D, Laquer V, et al. 726 - Interim results from ADmirable, a phase 3b open-label study assessing lebrikizumab in patients with skin of color and moderate-to-severe atopic dermatitis. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae266.099.","journal-title":"Br J Dermatol"},{"issue":"3","key":"3440_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.alit.2022.04.003","volume":"71","author":"M Tominaga","year":"2022","unstructured":"Tominaga M, Takamori K. Peripheral itch sensitization in atopic dermatitis. Allergol Int. 2022;71(3):265\u201377. https:\/\/doi.org\/10.1016\/j.alit.2022.04.003.","journal-title":"Allergol Int"},{"issue":"2","key":"3440_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaci.2019.06.016","volume":"144","author":"TB Yang","year":"2019","unstructured":"Yang TB, Kim BS. Pruritus in allergy and immunology. J Allergy Clin Immunol. 2019;144(2):353\u201360. https:\/\/doi.org\/10.1016\/j.jaci.2019.06.016.","journal-title":"J Allergy Clin Immunol"},{"key":"3440_CR31","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.1000110","author":"EB Brandt","year":"2011","unstructured":"Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011. https:\/\/doi.org\/10.4172\/2155-9899.1000110.","journal-title":"J Clin Cell Immunol"},{"issue":"1","key":"3440_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jaci.2020.05.048","volume":"147","author":"H He","year":"2021","unstructured":"He H, Bissonnette R, Wu J, Diaz A, Saint-Cyr Proulx E, Maari C, et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2021;147(1):199\u2013212. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.048.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3440_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-228 e13.","journal-title":"Cell"},{"issue":"3","key":"3440_CR34","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaci.2022.01.028","volume":"150","author":"Y Miron","year":"2022","unstructured":"Miron Y, Miller PE, Hughes C, Indersmitten T, Lerner EA, Cevikbas F. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2022;150(3):690\u2013700. https:\/\/doi.org\/10.1016\/j.jaci.2022.01.028.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3440_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jaci.2023.05.004","volume":"152","author":"L Misery","year":"2023","unstructured":"Misery L, Pierre O, Le Gall-Ianotto C, Lebonvallet N, Chernyshov PV, Le Garrec R, et al. Basic mechanisms of itch. J Allergy Clin Immunol. 2023;152(1):11\u201323. https:\/\/doi.org\/10.1016\/j.jaci.2023.05.004.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"3440_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/exd.13533","volume":"27","author":"C Nakashima","year":"2018","unstructured":"Nakashima C, Otsuka A, Kabashima K. Interleukin-31 and interleukin-31 receptor: new therapeutic targets for atopic dermatitis. Exp Dermatol. 2018;27(4):327\u201331. https:\/\/doi.org\/10.1111\/exd.13533.","journal-title":"Exp Dermatol"},{"issue":"1","key":"3440_CR37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaci.2021.01.001","volume":"148","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Del Duca E, Pavel AB, Fang M, Lefferdink R, Wu J, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148(1):148\u201363.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"3440_CR38","first-page":"S364","volume":"143","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Okragly A, Sun Z, Mena LR, Hahn N, Nickoloff BJ, et al. 190 lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis. J Investig Dermatol. 2023;143(11):S364.","journal-title":"J Investig Dermatol"},{"issue":"4","key":"3440_CR39","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s12325-024-02802-3","volume":"41","author":"A Rams","year":"2024","unstructured":"Rams A, Baldasaro J, Bunod L, Delbecque L, Strzok S, Meunier J, et al. Assessing itch severity: content validity and psychometric properties of a patient-reported pruritus numeric rating scale in atopic dermatitis. Adv Ther. 2024;41(4):1512\u201325.","journal-title":"Adv Ther"},{"issue":"2","key":"3440_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/bjd\/ljad435","volume":"190","author":"G Yosipovitch","year":"2024","unstructured":"Yosipovitch G, Lio PA, Rosmarin D, Serra-Baldrich E, Legat FJ, Casillas M, et al. Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2024;190(2):289\u201391. https:\/\/doi.org\/10.1093\/bjd\/ljad435.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3440_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12325-024-02974-y","volume":"42","author":"E Simpson","year":"2025","unstructured":"Simpson E, Fernandez-Penas P, de Bruin-Weller M, Lio PA, Chu CY, Ezzedine K, et al. Improvement across dimensions of disease with lebrikizumab use in atopic dermatitis: two phase 3, randomized, double-blind, placebo-controlled monotherapy trials (ADvocate1 and ADvocate2). Adv Ther. 2025;42(1):132\u201343.","journal-title":"Adv Ther"},{"issue":"6","key":"3440_CR42","doi-asserted-by":"publisher","DOI":"10.25251\/skin.7.supp.273","volume":"7","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Zeidler C, Apfelbacher CJ, Laquer V, Kim BS, Casillas M, et al. Lebrikizumab delivers clinically meaningful and continuous improvement in itch-free days in atopic dermatitis through one year. SKIN J Cutan Med. 2023;7(6):s273. https:\/\/doi.org\/10.25251\/skin.7.supp.273.","journal-title":"SKIN J Cutan Med"},{"key":"3440_CR43","doi-asserted-by":"publisher","first-page":"AB58","DOI":"10.1016\/j.jaad.2024.07.240","volume":"91","author":"G Yosipovitch","year":"2024","unstructured":"Yosipovitch G, Lio P, Rosmarin D, Casillas M, Yang FE, Hu C, et al. 51219 lebrikizumab monotherapy maintained improvement of itch and sleep-loss due to itch after two years in patients with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2024;91:AB58.","journal-title":"J Am Acad Dermatol"},{"key":"3440_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.082","author":"E Simpson","year":"2024","unstructured":"Simpson E, Biedermann T, Kircik L, Chovatiya R, Figueras-Nart I, Casillas M, et al. 708 - Raising the bar of efficacy in atopic dermatitis: lebrikizumab maintains depth of response over 2 years. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae266.082.","journal-title":"Br J Dermatol"},{"issue":"6","key":"3440_CR45","doi-asserted-by":"publisher","DOI":"10.25251\/skin.7.supp.271","volume":"7","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Weidinger S, Simpson E, Gooderham M, Irvine AD, Spelman L, et al. Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis. SKIN J Cutan Med. 2023;7(6):s271. https:\/\/doi.org\/10.25251\/skin.7.supp.271.","journal-title":"SKIN J Cutan Med"},{"issue":"8","key":"3440_CR46","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s13555-024-01226-9","volume":"14","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Stein Gold L, Del Rosso J, Yosipovitch G, Lio P, et al. Patients with moderate-to-severe atopic dermatitis maintain stable response with no or minimal fluctuations with 1 year of lebrikizumab treatment. Dermatol Ther (Heidelb). 2024;14(8):2249\u201360.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"3440_CR47","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","volume":"22","author":"T Bieber","year":"2023","unstructured":"Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22(8):662\u201380.","journal-title":"Nat Rev Drug Discov"},{"key":"3440_CR48","doi-asserted-by":"crossref","unstructured":"Chovatiya R, Simpson E, Biedermann T, Kircik L, Shi VY, Figueras\u2011Nart I, Casillas M, Gallo G, Ding Y, Zhang H, Pierce E, Agell H, Vestergaard C. Achieving depth of response in skin clearance and itch relief with lebrikizumab is associated with minimal impact of atopic dermatitis on quality of life. In: Fall clinical dermatology conference 2024; 2025-01-13, Las Vegas, USA, SKIN J Cutan Med; 2025.","DOI":"10.25251\/skin.9.supp.516"},{"issue":"1","key":"3440_CR49","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2324833","volume":"35","author":"AA Hebert","year":"2024","unstructured":"Hebert AA, Flohr C, Hong HC, Irvine AD, Pierce E, Elmaraghy H, et al. Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials. J Dermatolog Treat. 2024;35(1):2324833. https:\/\/doi.org\/10.1080\/09546634.2024.2324833.","journal-title":"J Dermatolog Treat"},{"key":"3440_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.010","author":"A Armstrong","year":"2024","unstructured":"Armstrong A, Zirwas M, Napolitano M, Torres T, Staumont-Salle D, Atwater AR, et al. 626\u2014Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients \u226560 years of age. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae266.010.","journal-title":"Br J Dermatol"},{"issue":"9","key":"3440_CR51","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s13555-023-00980-6","volume":"13","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Shi VY, Alexis A, Pierce E, Cronin A, McLean RR, et al. Racial and ethnic differences in sociodemographic, clinical, and treatment characteristics among patients with atopic dermatitis in the United States and Canada: real-world data from the CorEvitas atopic dermatitis registry. Dermatol Ther. 2023;13(9):2045\u201361.","journal-title":"Dermatol Ther"},{"issue":"Supplement_2","key":"3440_CR52","doi-asserted-by":"publisher","first-page":"ii20","DOI":"10.1093\/bjd\/ljad498.024","volume":"190","author":"A Alexis","year":"2024","unstructured":"Alexis A, Ardern-Jones M, Chovatiya R, Flohr C, Irvine A, AlMurrawi M, et al. 517\u2014Lebrikizumab demonstrates significant efficacy versus placebo across racial and ethnic subgroups in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2024;190(Supplement_2):ii20\u20131.","journal-title":"Br J Dermatol"},{"issue":"5","key":"3440_CR53","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.mayocp.2020.08.033","volume":"96","author":"KD Gandhi","year":"2021","unstructured":"Gandhi KD, Mansukhani MP, Silber MH, Kolla BP. Excessive daytime sleepiness: a clinical review. Mayo Clin Proc. 2021;96(5):1288\u2013301.","journal-title":"Mayo Clin Proc"},{"key":"3440_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1047","volume":"368","author":"J Brown","year":"2020","unstructured":"Brown J, Makker HK. An approach to excessive daytime sleepiness in adults. BMJ. 2020;368:m1047.","journal-title":"BMJ"},{"issue":"S1","key":"3440_CR55","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1089\/derm.2023.0074","volume":"35","author":"A Samynathan","year":"2024","unstructured":"Samynathan A, Fishbein AB, Abbott SM, Booster GD, Zee PC, Sheldon SH, et al. Assessment and management of sleep disturbances in atopic dermatitis: a review. Dermatitis. 2024;35(S1):S7\u201312.","journal-title":"Dermatitis"},{"issue":"5","key":"3440_CR56","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s13555-024-01153-9","volume":"14","author":"EJ Pierce","year":"2024","unstructured":"Pierce EJ, Burge RT, Hirst AJ, Fox AM, Suokas AK, Yi Y. Economic burden of itch-related sleep loss in moderate-to-severe atopic dermatitis in the United Kingdom. Dermatol Ther. 2024;14(5):1103\u201314.","journal-title":"Dermatol Ther"},{"key":"3440_CR57","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.34375","volume":"104","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Igawa K, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, et al. Lebrikizumab combined with topical corticosteroids improves patient-reported outcomes in Japanese patients with moderate-to-severe atopic dermatitis. Acta Derm Venereol. 2024;104:adv34375.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"3440_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2329240","volume":"35","author":"J Soung","year":"2024","unstructured":"Soung J, Stander S, Gutermuth J, Pau-Charles I, Dawson Z, Yang FE, et al. Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two phase 3 trials. J Dermatolog Treat. 2024;35(1):2329240. https:\/\/doi.org\/10.1080\/09546634.2024.2329240.","journal-title":"J Dermatolog Treat"},{"key":"3440_CR59","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/ced\/llae541","volume":"50","author":"G Yosipovitch","year":"2025","unstructured":"Yosipovitch G, de Bruin-Weller M, Wiseman M, Elberling J, Gutermuth J, Pierce E, et al. Improvement in quality of life in patients treated with lebrikizumab monotherapy is mediated by improvement in itch and sleep: results from two phase 3 trials in patients with moderate-to-severe atopic dermatitis. Clin Exp Dermatol. 2025;50:1188\u201392.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"3440_CR60","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s13555-025-01357-7","volume":"15","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Bieber T, Paller AS, Beck L, Kamata M, Puig L, et al. Lebrikizumab vs. other systemic monotherapies for moderate-to-severe atopic dermatitis: network meta-analysis of efficacy. Dermatol Ther (Heidelb). 2025;15(3):615\u201333.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"24","key":"3440_CR61","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"2","key":"3440_CR62","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran M, Thaci D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377\u201388. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.074.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3440_CR63","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"10451","key":"3440_CR64","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","volume":"404","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Reich A, Thaci D, Legat FJ, Papp KA, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024;404(10451):445\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(24)01203-0.","journal-title":"Lancet"},{"issue":"3","key":"3440_CR65","doi-asserted-by":"publisher","first-page":"AB307","DOI":"10.1016\/j.jaad.2024.07.1223","volume":"91","author":"LS Gold","year":"2024","unstructured":"Gold LS, Thaci D, Katoh N, Shi V, Irvine A, BuziquiPiruzeli ML, et al. 52041 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: integrated analysis from 10 clinical trials. J Am Acad Dermatol. 2024;91(3):AB307.","journal-title":"J Am Acad Dermatol"},{"key":"3440_CR66","doi-asserted-by":"publisher","first-page":"1429709","DOI":"10.3389\/fphar.2024.1429709","volume":"15","author":"J Lin","year":"2024","unstructured":"Lin J, Luo M, Zhuo Q, Chen N, Zhang H, Han Y. Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1429709.","journal-title":"Front Pharmacol"},{"key":"3440_CR67","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761306s003lbl.pdf. Accessed 16 Oct 2025."},{"key":"3440_CR68","doi-asserted-by":"publisher","first-page":"100054","DOI":"10.1016\/j.plas.2022.100054","volume":"3","author":"C Unterhitzenberger","year":"2022","unstructured":"Unterhitzenberger C, Lawrence K. Diary method in project studies. Proj Leadersh Soc. 2022;3:100054.","journal-title":"Proj Leadersh Soc"},{"key":"3440_CR69","doi-asserted-by":"crossref","unstructured":"Ebata T. Measurement of Itch: Actigraphy. In: Misery L, St\u00e4nder S, editors. Pruritus. Cham: Springer International Publishing; 2016. pp. 97\u2013101.","DOI":"10.1007\/978-3-319-33142-3_13"},{"key":"3440_CR70","unstructured":"Davis DMR, Frazer-Green L, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Focused update: Guidelines of care for the management of atopic dermatitis in adults. J Am Acad Dermatol. 2025."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03440-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03440-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03440-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:50Z","timestamp":1771268630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03440-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3440"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03440-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gil Yosipovitch has participated as a Consultant or Board Member for Sanofi, Regeneron, Galderma, Pfizer, Novartis, Eli Lilly, AbbVie, Arcutis, Vifor, Kamari, Kiniksa, Trevi Therapeutics, Pierre Fabre, LEO Pharma, Escient Health, Celldex, and GSK. He has received research support from Pfizer, Sanofi, Regeneron, LEO, Eli Lilly, Kiniksa, Novartis, Escient, Bellus, Galderma, and Celldex. Brian S. Kim is co-founder of Alys Pharmaceuticals; he has served as a consultant for 23andMe, ABRAX Japan, AbbVie, Amgen, Attovia Therapeutics, Cara Therapeutics, Clexio Biosciences, Eli Lilly and Company, Escient Pharmaceuticals, Evommune, Galderma, LEO Pharma, Micreos, Novartis, Pfizer, Recens Medical, Regeneron, Sanofi, Septerna, Teva, Trevi Therapeutics, Triveni Bio; he has stock in ABRAX Japan, Alys Pharamaceuticals, Attovia Therapeutics, Locus Biosciences, Recens Medical and Triveni Bio; he holds a patent for the use of JAK1 inhibitors for chronic pruritus. Sonja St\u00e4nder was speaker and\/or consultant and\/or investigator and\/or has received research funding from Almirall S. A., Amgen Inc., Amgen Europe GmbH, Celldex Therapeutics Inc., Clexio Biosiences Ltd., Focus-Insight Healthtech Group Co. Ltd., Galderma Laboratorium GmbH, Galderma R&D LLC., Galderma S.A., GSK R&D Ltd., Incyte Corporation, Klirna Biotech Inc., Leo Pharma, Lilly Deutschland GmbH, Novartis Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis R&D, Sanofi Genzyme Corporation, TouchIME, Vifor Pharma Deutschland GmbH P. G. Unna Academy. Sarina B. Elmariah has served as an advisory board member, consultant or received honoraria from Celldex, Galderma, Eli Lilly, New Frontier Bio, Novartis, Pfizer, Regeneron, and Sanofi. Vimal H. Prajapati has been an advisor, consultant, and\/or speaker for: AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP\/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, Cipher, CorEvitas, Eczema Society of Canada, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, J&J Innovative Medicine, Janssen, Johnson & Johnson, LEO Pharma, Medexus, Novartis, Organon, Paladin, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, and UCB; investigator for: AbbVie, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, J&J Innovative Medicine, Janssen, LEO Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne Therapeutics; and received grants from: AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Kenji Kabashima has received consulting fees, honoraria, grant support, and\/or lecture fees from AbbVie, Amgen, Eli Lilly, Kyowa Kirin, Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe, Ono Pharmaceutical, Pfizer, Procter & Gamble, Sanofi, Regeneron, Taiho, and TORII Pharmaceutical. Gaia Gallo, Maria Jose Rueda, Evangeline Pierce, and Yuxin Ding are employees and shareholders of Eli Lilly and Company. Shawn Kwatra is an advisory board member or consultant for AbbVie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermavant, Galderma, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}